Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

To be able to join this study, you would generally need to have head and neck squamous cell carcinoma that has either spread or come back after previous treatment and can't be removed by surgery. Importantly, you shouldn't have received any other treatments for this advanced stage of your cancer yet. Your cancer also needs to show certain features that indicate it might respond to the treatments being studied.

Your general health is also important. This includes having healthy bone marrow (which makes blood cells), good kidney and liver function, and a good overall physical ability to carry out daily activities. You must be at least 18 years old to participate.

There are also some reasons why you wouldn't be able to join. For example, if your cancer has spread to your brain and is causing severe symptoms, or if you have a history of certain lung problems that needed strong medication. Also, if you've previously been treated with similar types of immune-boosting drugs that are being tested in this trial, you wouldn't be able to take part.

If you decide to take part, you'll first go through some screening tests to see if the study is right for you. If you qualify, you'll be randomly assigned to one of two groups: either you'll receive the new drug evorpacept plus pembrolizumab, or you'll receive pembrolizumab alone. This is like flipping a coin – neither you nor the doctors decide which group you're in, which helps make the study fair.

The treatments will be given through injections or infusions, typically at a clinic or hospital. You'll have regular visits for blood tests, physical exams, and scans (like CT or MRI) to check how you're responding to the treatment and to monitor for any side effects. The study involves ongoing treatment and visits as long as the treatment is working and you are tolerating it well. After you stop treatment, there will be follow-up visits or calls to monitor your health over a longer period. The total duration of your involvement could vary depending on your response to treatment and the follow-up schedule.